---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-002496"
form_type: "8-K"
ticker: "AQST"
cik: "0001398733"
company_name: "Aquestive Therapeutics, Inc."
filed_at: "2023-02-07T23:59:59+00:00"
generated_at: "2026-06-19T22:44:19.623874+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# Aquestive amends bylaws to update stockholder meeting procedures and director nomination requirements

## Summary
- Bylaws amended to eliminate requirement to re-notice adjourned meetings if time/date/place announced or in original notice.
- Removed requirement to make stockholder list available for inspection during meetings.
- Added enhanced director nomination requirements: background info, Universal Proxy Rule compliance, limit nominees to board seats.
- Nominees must provide representation on voting/compensation arrangements and compliance with laws and company policies.

## SEC filing metadata
- accession: 0001628280-23-002496
- form_type: 8-K
- ticker: AQST
- cik: 0001398733
- company_name: Aquestive Therapeutics, Inc.
- filed_at: 2023-02-07T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1398733/000162828023002496/0001628280-23-002496-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1398733/000162828023002496/aqst-20230202.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-002496
- JSON: https://secwatch.observer/filing/0001628280-23-002496.json
- Plain text: https://secwatch.observer/filing/0001628280-23-002496.txt

## Key facts
- Governance Changes
  Aquestive Therapeutics, Inc.: Amended and restated Bylaws to update provisions on adjourned stockholder meetings, stockholder list inspection, and director nomination requirements, including compliance with Universal Proxy Rules (effective 2023-02-02).
  - Change: bylaw amendment
  - Effective: 2023-02-02
  source text: On February 2, 2023, the Board of Directors (the “Board”) of Aquestive Therapeutics, Inc. (the “Company”) amended and restated the Company’s Amended and Restated Bylaws, as amended (the “Bylaws”), effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1398733/000162828023002496/0001628280-23-002496-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.